While there’s no cure for multiple sclerosis (MS), there are many treatments available. These treatments mainly focus on slowing down the progression of the disease and managing symptoms.

The FDA has advised health care professionals and patients with multiple sclerosis that treatment with glatiramer acetate is ...

The National Multiple Sclerosis Society (NMSS) has launched the first national guidelines for the treatment of Multiple ...

Relapsing-remitting multiple sclerosis is a type of multiple sclerosis ... or months until symptoms slowly improve, with or without treatment. Between RRMS relapses, you will experience periods ...

Graham has had a “crash course in MS” after his diagnosis last year, and is willing to do “whatever it takes” to raise funds ...

A new online guide has launched to support and empower people with vulval lichen sclerosus (LS) to learn about the condition, ...

Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics ...

The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment.

The study identified gene expression changes which were detected beginning three months after intranasal dosing of foralumab in our ongoing ISPPEA (or expanded access program). Key findings include ...

Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for ...

Zydus’ Usnoflast receives US FDA orphan drug designation to treat amyotrophic lateral sclerosis: Our Bureau, Mumbai Thursday, January 23, 2025, 12:15 Hrs [IST] Zydus, a leading, ...